Who was studied?
37 patients enrolled; after seven exclusions, 30 formed the authors’ ITT/safety population, and 26 were assessed for response.
What does the publication report?
Among 26 response-assessed patients, six had partial response and 11 stable disease: ORR 23.08% (6/26), DCR 65.38% (17/26). Reported median PFS was 3.5 months; OS remained immature.
Safety findings
Safety was assessed in 30 patients. Seventeen adverse events were reported, six grade 3 or 4; two grade 4 cytopenias occurred in the same patient. No grade 5 events were reported.
How should we interpret it?
Small, nonrandomized study with exclusions before analysis. The authors label a post-exclusion population ITT, which requires reading alongside the patient flow. This independent regimen should not be equated with PRaG 5.0.
Read the original source
This independently written summary was checked against the original full publication. It is an educational summary, not a full-paper translation or clinical recommendation.
Hypofractionated radiotherapy combined with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor, and thymosin-α1 in advanced metastatic solid tumors: a multicenter Phase II clinical trial · DOI: 10.1007/s00262-024-03934-9 · PMID: 39904914
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.